Back to News
Market Impact: 0.32
Corcept Grows to Mid-Cap on Institutional Support
Source: fxempire.com
Market Technicals & FlowsInvestor Sentiment & PositioningHealthcare & BiotechCompany Fundamentals
Corcept Therapeutics shares have risen 1,016% since 2017, driven by sustained large-volume institutional buying. The company is nearing inclusion in the S&P MidCap 400, a potential catalyst for additional index-fund demand and investor visibility.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
CORT0.78
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- FBI blames North Korea for record $6.3bn crypto heist
- Binance to resume crypto withdrawals in phases after record $6 billion hack
- AWS grows 39% and Amazon will spend even more on AI in 2027
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded